title: Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic.
abstract: BACKGROUND
  Scalp psoriasis, one of the most common sites of psoriasis involvement, is often difficult to control with topical agents. There is a lack of substantial evidence-based data for the efficacy and safety of systemic therapies.
  
  
  METHODS
  Two patients from our university-based psoriasis clinic with chronic plaque psoriasis and severe recalcitrant scalp involvement were assessed by Psoriasis Area and Severity Index and Psoriasis Scalp Severity Index scores, respectively, and quality of life by the Dermatology Life Quality Index.
  
  
  RESULTS
  We report 2 psoriasis patients with very severe scalp psoriasis who developed a fast clinical response of scalp psoriasis to ustekinumab in 8 weeks with excellent patient adherence up to 28 weeks of follow-up and positive impact on quality of life due to rapid and long-term clearing.
  
  
  CONCLUSIONS
  Ustekinumab produces a fast clinical response of recalcitrant scalp psoriasis with excellent patient adherence and a positive impact on quality of life due to rapid and long-term clearing in patients with very severe scalp involvement who failed conventional topical and systemic treatment.
authors: 2nd Department of Dermatology and Venereology, Attikon University Hospital, Athens, Greece.
authors: E
authors: E
authors: Papadavid
authors: D
authors: D
authors: Ferra
authors: D
authors: D
authors: Koumaki
authors: M
authors: M
authors: Dalamaga
authors: C
authors: C
authors: Stamou
authors: K
authors: K
authors: Theodoropoulos
authors: D
authors: D
authors: Rigopoulos
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006115:Greece; D006785:Hospitals, University; D006801:Humans; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D011788:Quality of Life; D012536:Scalp Dermatoses / Q000188:drug therapy* / Q000473:pathology*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069549:Ustekinumab